Literature DB >> 11256485

Effect of lipophilicity on in vivo iontophoretic delivery. I. NSAIDs.

Y Tashiro1, S Shichibe, Y Kato, E Hayakawa, K Itoh.   

Abstract

The effect of drug lipophilicity on in vivo iontophoretic transdermal absorption was evaluated. Non-steroidal anti-inflammatory drugs (NSAIDs) were selected as model drugs with a wide range of lipophilicity: salicylic acid (SA), ketoprofen (KP), naproxen (NP) and indomethacin (IM). Cathodal iontophoresis of NSAIDs was conducted in rats (0.625 mA/cm2; 90 min), and drug concentrations in skin, cutaneous vein and systemic vein were determined. Skin concentrations of NSAID were higher in the case of lipophilic drugs (SA=KP=NP<IM), whereas cutaneous plasma concentrations decreased with an increase in lipophilicity (SA>KP=NP>IM). Additionally, the dependence of drug lipophilicity on systemic plasma concentration was similar to cutaneous plasma concentration. The transfer rate from skin to cutaneous vein (R(SC)) was calculated from the arterio-venous plasma concentration difference of drug in the skin. Normalized R(SC) by skin concentration (R(SC)/X(S)) yielded a negative correlation with the logarithm of n-octanol/buffer partition coefficient (Log P at pH 7.4), suggesting that transfer of NSAIDs from skin to cutaneous vein decreased with increasing lipophilicity (SA>KP=NP>IM). This correlation means that drug partitioning between stratum corneum and viable epidermis might be a dominant step.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11256485     DOI: 10.1248/bpb.24.278

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  2 in total

1.  Quantitative structure-permeation relationship for iontophoretic transport across the skin.

Authors:  Blaise Mudry; Pierre-Alain Carrupt; Richard H Guy; M Begoña Delgado-Charro
Journal:  J Control Release       Date:  2007-07-19       Impact factor: 9.776

2.  Transdermal iontophoretic delivery of celecoxib from gel formulation.

Authors:  Naser Tavakoli; Mohsen Minaiyan; Mojtaba Heshmatipour; Ruholla Musavinasab
Journal:  Res Pharm Sci       Date:  2015 Sep-Oct
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.